CLDX logo

CLDX Celldex Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$27.55
-0.49 (-1.75%)

Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and …

Market Cap: $2.16Bwww.celldex.com

Price

No data yet.

Social Signal Score

48
5d
50
1 mentions
—
30d
50
2 mentions
—
60d
50
2 mentions
—
90d
40
6 mentions
—
news: 6

Analyst Ratings

20 analysts
Buyconsensus
Strong Buy 0Buy 17Hold 3Sell 0Strong Sell 0
Avg price target$66.8+142.5%
Low $45Median $62.5High $100
Current Consensus

Revenue

$0.00-100.00%
$0.00$1.38M$2.75M$4.13M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-3.71
$-3.88–$-3.38
9 analysts
FY2026
$-4.08
$-4.12–$-4.01
7 analysts
FY2027
$-4.00
$-4.45–$-3.60
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Anthony S. Marucci
Sector
Healthcare
Industry
Biotechnology
Employees
198
Beta
0.90
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
13.97
www.celldex.com